InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09 2021 - 7:18PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the manufacturing and
clinical development of rare cannabinoids, today
announced that Eric. A. Adams, President and CEO of InMed will
present at the H.C. Wainwright 23rd Annual Global Investment
Conference which is being held virtually from September 13-15,
2021.
The on-demand presentation will be available at
1:00 pm ET on September 13, 2021 and can be accessed from the H.C.
Wainwright events platform at HCW Events. An archived replay of the
presentation will be available on the Company’s website immediately
following the conference and will be available for 90 days.
InMed’s management team will also be conducting
meetings with institutional investors throughout the conference. To
schedule a meeting, please contact your H.C. Wainwright
representative or register for the event at HCW Events.
Information on this event will also be posted on InMed’s event
page, which can be found
at: www.inmedpharma.com/about/events.
About InMed: InMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”), and is
developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: presenting at H.C. Wainwright 23rd Annual Global
Investment Conference; delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based pharmaceutical
drugs; advancing IntegraSyn™ to commercial scale production;
IntegraSyn™ being a commercially viable solution for large-scale,
pharmaceutical-grade GMP production of rare cannabinoids; and
developing a pipeline of cannabinoid-based pharmaceutical drug
candidates. All forward-looking information herein is qualified in
its entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024